Product news from the 08/01/06 News Brief

Share this article:
Product news Takeda Pharmaceuticals North America said the FDA has approved its New Drug Application for Duetact (pioglitazone HCl and glimepiride), for the treatment of type 2 diabetes. Duetact combines the diabetes medications Actos (pioglitazone HCl) and glimepiride in a single tablet. The FDA has approved the expanded indication of Abbott’s rheumatoid arthritis treatment Humira (adalimumab) for reducing signs and symptoms in patients with active ankylosing spondylitis (AS), an autoimmune disease affecting the spine and large peripheral joints that causes inflammatory back pain and stiffness and also can be associated with other inflammatory diseases of the skin, eyes and intestines.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.